Thomas E. Hutson, DO, PharmD, FACP, is the director of the Genitourinary Oncology Program and Co-Director of the Center of Excellence for Texas Oncology in the Charles A. Sammons Cancer Center at Baylor University Medical Center; and Co-Chair of Genitourinary Research for US Oncology. In addition, he is a Professor of Medicine at Texas A&M Health Science Center College of Medicine. Dr. Hutson's main research interests focus on improving outcomes in patients with renal cell carcinoma through the use of novel and targeted agents. Toward this end, he has served as the Principal Investigator for multiple clinical trials investigating novel therapies in renal cell carcinoma, bladder cancer, and prostate cancer. His research has resulted in over one hundred fifty publications including chapters in medical textbooks on Prostate Cancer and Renal Cell Carcinoma. Dr. Hutson received a bachelor's degree in Pharmacy from Ohio Northern University in 1993 and in 1997 he obtained the Doctor of Osteopathic Medicine degree from Ohio University College of Osteopathic Medicine. He completed his internship, internal medicine residency, and fellowships in Experimental Therapeutics and Hematology/Medical Oncology in 2003 at The Cleveland Clinic Foundation. In 2002, Dr. Hutson received his Doctor of Pharmacy degree, with high distinction, from Ohio Northern University. As a internationally recognized opinion leader in the field of Genitourinary Oncology, Dr. Hutson serves on the editorial boards of Clinical Prostate Cancer, Clinical Genitourinary Cancer, Kidney Cancer Journal, Expert Review of Anticancer Therapy, Cure, Cancer.Net, and MedTrust and is a reviewer for several other journals, including Cancer, Lancet, and Lancet Oncology. Faith, and the relationship between religion and medicine, has been of particular importance to Dr. Hutson, especially in the area of end of life (EOL) care. To further increase his own knowledge in this subject he has enrolled into the Master of Theology (ThM) program at the prestigious Dallas Theological Seminary where he is working with the Academic Dean on curriculum to improve education of clergy and health care providers. Dr. Hutson also serves as the medical director for Holy Savior Hospice in Dallas, Texas. Dr. Hutson is married to Kimberly Hodges Hutson. The couple and their two sons, Jacob and Kyle, reside in Plano, Texas.

Emiliano Calvo, M.D., Ph.D., is the Director of START Madrid Group in Madrid (Early Phase Clinical Drug Development in Oncology, international program) and the Director of Clinical Research at the START Madrid-Centro Integral Oncológico Clara Campal hospital, in Madrid, Spain, from its launch in 2008. He is also the President of the Investigational Therapeutics in Oncological Sciences Foundation (Intheos). In addition, he is an Associate Professor at University CEU San Pablo in Madrid, Spain, Faculty member (from 2012) and ESMO Director at the International Workshop in Methods in Clinical Cancer Research, in Flims, Switzerland (2017-2019), and Track Leader (2015-6) and Committee member (from 2014) for the Scientific Program Committee on the Developmental Therapeutics - Clinical Pharmacology & Experimental Track of the Annual Meetings of the American Society of Clinical Oncology (ASCO), as well as honorary member of the Cancer Education Committee of ASCO (2015-2016). During 2006-2011 and from 2015 on, he is a Faculty Member of the ESMO (European Society of Medical Oncology) Educational Committee, for the special expertise group “Principles of Clinical Trials and Systemic Therapy”, and, also, from 2014 Faculty member of the ESMO Educational Committee for the special expertise group “non-prostate genitourinary tumors”. In addition, he has been a member of the Scientific Committee of the ESMO-ECCO anual meeting (2008, 2009 and 2011 –Developmental Therapeutics track-) and, from 2015, at the annual EORTC-NCI-AACR International Conference on Molercular Targets and Cancer Therapeutics He earned his M.D. in 1993 at the Universidad Autónoma de Madrid in Madrid, Spain and his Ph.D. in 2003 at the Universidad de Navarra in Pamplona, Spain, with highest commendation. He trained in Medical Oncology at the Clínica Universitaria de Navarra in Pamplona, Spain and completed his Advanced Fellowship in Drug Development at the Cancer Therapy & Research Center’s Institute for Drug Development in San Antonio, Texas, from 2003 to 2005, where he was a Senior Fellow and Clinical Investigator. While working in the Medical Oncology Department at the Hospital Vall d'Hebron in Barcelona, Spain, from 2005 to 2008, Dr. Calvo was Co-Director and Senior Researcher of the Phase I Unit and director of the Genitorurinary Tumors Program. Dr. Calvo has co-authored approximately one hundred publications, especially regarding clinical development of new drugs in different tumor types and in kidney cancer. These publications include scientific articles, chapters in oncology books and presentations at different major conferences and meetings. During these last 12 years of almost full dedication to Clinical Drug development in Oncology, he has participated in around two hundred international studies, as a clinical investigator, specially in Early Clinical Drug Development and in kidney cancer. He serves as an ad-hoc reviewer of various oncology journals, recently named board editor for European Journal of Cancer, and is a panel expert advisor at multiple Advisory Boards of anticancer drug development and kidney cancer therapeutics.

Stéphane Oudard is a Professor of Oncology and Chief of the Oncology Clinical and Translational Research Unit at the Georges Pompidou Hospital in Paris, France. Professor Oudard received his medical degree from Hôtel-Dieu Hospital, University of Paris, France (1993). On completion of his residency in medical oncology in Paris, Professor Oudard obtained his Masters of Science at Lariboisière-Saint Louis University Hospital, Paris, France (1994) and his Doctorate at Institut Curie, Paris, France (1996). He completed a 2-year fellowship in cancer research at Georgetown University, Washington, DC, USA, before returning to Paris. Professor Oudard has authored more than 220 scientific articles and 40 literature reviews published in various international journals and is also a reviewer for several leading journals including Journal of Clinical Oncology, Annals of Oncology, European Urology and European Journal of Cancer. He is currently an active member of the French Cancer Society, European Society for Medical Oncology (ESMO), and American Society of Clinical Oncology (ASCO). As a clinical researcher, Professor Oudard has served as a Coordinator, Investigator, or Co-Investigator on several phase I−III French, European, and international clinical trials. He has been largely involved in the development of cabazitaxel, sorafenib, sunitinib and everolimus in uro-oncology tumors. His research interests include prostate and kidney cancers, translational research, angiogenesis, inhibition of glycolysis, and drug resistance. He is the principal investigator of the Rising PSA phase III trial and the PREDICT trial.

Dr. Roberto Iacovelli is a medical oncologist who is dedicated to clinical research and treatment of patients affected by genitourinary tumors. His primary areas of expertise are renal cell carcinoma and prostate cancer. He is author of more than one hundred articles, reviews and abstracts, most of these investigating the role of clinical and molecular prognostic factors in renal cell carcinoma and prostate cancer, other than sequencing therapies for metastatic renal cell carcinoma. In addition, he served as a reviewer for several international peer reviewed journals. For its research activity, Dr. Iacovelli received many awards and recognitions from national and international societies as the ASCO Cancer Foundation Merit Award at ASCO GU in 2011 and the best poster award in genitourinary oncology at the European Society of Medical Oncology Conference in 2012.

Go Kimura, MD, PhD is an Associate Professor of Urology at Nippon Medical School. He specializes in urologic oncology and urologic pathology.

Dr. Charles George Drake is an associate professor of oncology, urology and immunology at the Johns Hopkins School of Medicine. He also serves as Co-Director of the Prostate Cancer Multidisciplinary Clinic. His areas of expertise include immunotherapy and the diagnosis and treatment of cancers of the prostate, kidney, bladder and testes. Dr. Drake graduated with a B.S. in electrical engineering and M.S. in biomedical engineering from Rutgers University in Piscataway, NJ. He then received a Ph.D. in immunology from the National Jewish Center for Immunology, and in 1997 completed an M.D. at the University of Colorado Health Sciences Center. He conducted an internal medicine residency on the Osler Service at Johns Hopkins, and in 2002 he completed a fellowship in medical oncology, also at Johns Hopkins. He joined the Johns Hopkins faculty as an assistant professor in 2002. Dr. Drake has published extensively, has won numerous awards and honors for his research and scholarship, and holds several patents. He is a diplomate of Medical Oncology with the American Board of Medical Examiners and a member of the American Association of Immunology, the American Association for Cancer Research and the American Society of Clinical Oncology.

I trained in medicine at the Middlesex Hospital Medical School, London where I was awarded an intercalated BSc in 1984. I completed my basic medical training at the University of Cambridge School of Medicine and graduated MB BChir in 1986. After 4 years of general medical training I became a member of the Royal College of Physicians (UK) in 1990. Between 1991 and 1995 I was a clinical research fellow at the Marie Curie Research Institute in Surrey. During this time I completed a PhD on the molecular biology of melanoma. Following this I trained as a medical oncologist on the Senior Registrar rotation of the Royal Marsden Hospital, London and Surrey. I received my Certificate of Completion of Specialist Training in Medical Oncology in 1997. In 1998 I was appointed as Senior Lecturer in Medical Oncology at University College London where I developed special interests in the treatment of melanoma, renal carcinoma and lung cancer, as well as undertaking clinical research into these conditions. In February 2001 I took up a new post as Senior lecturer in Medical Oncology at the Institute of Cancer Research and the Royal Marsden Hospital. I became a fellow of the Royal College of Physicians in 2002. In October 2006 I took up a new post as Professor of Medical Oncology in the University of Cambridge. Since September 2014 I have been on leave of absence from the University of Cambridge to work 4 days per week as Chief Clinician Scientist of AstraZeneca; I continue to work on the treatment and research of kidney cancer for the rest of my working week.